Brought to you by 
CryoLife buys CardioGenesis for $22mm in cash
17 Nov 2017
Executive Summary
CryoLife Inc. (processes and preserves cardiac and vascular homografts for heart and blood vessel reconstructive surgery) has agreed to buy fellow public cardiovascular device company CardioGenesis Corp. for $22mm in cash, equal to $0.46 per share, a 53% premium.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
- Laser
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CryoLife buys CardioGenesis for $22mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice